The updated treatment approach will allow clinicians, based on individual patients’ outcomes, to lengthen the intervals between injections for patients with neovascular age-related macular degeneration (AMD) who are already in the first year of treatment. That could mean fewer injections and fewer trips to the clinic for patients with AMD.
Bayer has announced that the European Commission has approved a new treatment regimen for aflibercept (Eylea). The updated treatment approach will allow clinicians, based on individual patients’ outcomes, to lengthen the intervals between injections for patients with neovascular age-related macular degeneration (AMD) who are already in the first year of treatment. That could mean fewer injections and fewer trips to the clinic for patients with AMD.
Approval for the new regimen is based on findings from the phase 4 ALTAIR study1, which tested a so-called “treat-and-extend” approach to AMD at 40 sites in Japan. In the study, 255 patients were given 3 monthly doses of aflibercept, then randomized to either 2-week (n = 124) or 4-week (n = 123) intervals for injections. Intervals could be shortened or lengthened based on clinical factors, and the maximum interval was 16 weeks. Best corrected visual acuity gains were similar between the 2 groups at 52 weeks, with a mean gain of 9.0 letters for the 2-week group and 8.4 letters for the 4-week group.
Said Michael Devoy, MD, chief medical officer of Bayer, “This new treatment regimen for Eylea has the potential to reduce the number of injections and clinic visits to less than 4 in the second year for certain neovascular AMD patients, while still maintaining strong visual outcomes and the ability to see.”
Lower number of injections could also make a difference in costs. Aflibercept is more expensive than its fellow anti-vascular endothelial growth factor treatment bevacizumab, which is routinely used off-label to treat eye disorders. Recent reports have questioned whether aflibercept can compete with bevacizumab in terms of value; one paper from Europe suggested that, for aflibercept to be a justifiable alternative to bevacizumab, aflibercept should be reduced from €943 (approximately $1100) to €533 (approximately $622) per injection.
In addition to pressure to compete on cost, aflibercept is also being targeted by a number of biosimilar developers; Momenta Pharmaceuticals and Mylan have announced that they will begin a pivotal clinical trial of their jointly developed M710, and Alteogen has announced that it will file and Investigational New Drug application for its ALT-L9.
Reference
Wai KM, Singh RP. Treat and extend dosing regimen with anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration. Am J Ophthalmic Clin Trails. 2018;1(1): 1-6. doi: 10.25259/AJOCT-2-2018.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
April 16th 2023What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.